Retina UK: Gene therapy for RPE65 gene approved for use in EU

23 November 2018
Source: Retina UK

The gene therapy Luxturna has won European regulatory approval for the treatment of Inherited retinal dystrophy caused by mutations in the RPE65 gene. This milestone decision was made by the European Medicines Agency (EMA) on Thursday, 22 November. Luxturna is the first and only gene therapy available in Europe to treat inherited retinal disease. It had already been approved for

Read more Retina UK: Gene therapy for RPE65 gene approved for use in EU